Impact Biomedical Inc. (IBO) announced that it has amended the terms of its pending reverse merger with Dr. Ashleys Bio Labs. The amendment was disclosed on March 4 2026 and became effective on February 27 2026, extending the merger’s end date from March 31 to July 1 2026.
Key provisions of the revised agreement include a share allocation of 169,560,000 PubCo ordinary shares, representing 94.20 % of the combined company at closing before certain deductions. The agreement also specifies that 22,000 compensation shares for Impact’s CEO and up to 128,000 shares for DSS, Inc. will be deducted from Dr. Ashleys’ share of the consideration. DSS, Inc. has agreed to provide new funding and hold‑harmless obligations in exchange for up to 128,000 PubCo shares, with 53,000 shares issued at closing and the remaining 75,000 upon full performance of the conditions.
Impact Biomedical has faced significant financial challenges, including operating losses and a going‑concern warning as of Q3 2025. The company’s limited cash reserves have heightened the urgency of completing the merger, which is viewed as a critical step toward preserving shareholder value and avoiding a liquidity crisis.
Dr. Ashleys Bio Labs is a global pharmaceutical company that specializes in the development and manufacturing of active pharmaceutical ingredients and orphan drugs, with a focus on oncology, malaria, and infectious diseases. Its broad market reach and manufacturing capabilities complement Impact Biomedical’s innovation‑driven platform and patent portfolio.
DSS, Inc. is the parent company of Impact Biomedical and holds approximately 88.87 % of IBO shares on a fully diluted basis. By continuing to provide financial backing and agreeing to the share‑deduction terms, DSS, Inc. reinforces its commitment to the transaction and helps secure the necessary capital for the combined entity.
The amended terms are designed to strengthen the combined company’s market position by extending the timeline for closing, clarifying the share structure, and ensuring continued financial support from DSS, Inc. These changes address prior investor concerns about the merger’s value proposition and provide a clearer path to liquidity for Impact Biomedical, which has been under pressure due to its financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.